Gilead Sciences Surges as $1.34 Billion Trading Volume Tops the Market

Market Snapshot

Shares of Gilead Sciences Inc. (NASDAQ: GILD) exhibited robust trading activity on Tuesday, August 4, 2026, closing with a gain of 3.13%. The biopharmaceutical giant saw its turnover volume surge significantly, reaching $1.34 billion, which marked a 37.06% increase from the previous day’s levels. This heightened liquidity propelled Gilead to the top spot for trading volume across the broader market for the session. The substantial uptick in transaction value underscores intense investor interest surrounding the company’s second-quarter earnings release, reflecting a market eager to digest the implications of recent strategic acquisitions and the underlying strength of its core product portfolio.

Key Drivers

Gilead Sciences delivered a complex financial narrative for the second quarter of 2026, characterized by a stark divergence between top-line revenue growth and bottom-line profitability. The company reported total revenue of $7.8 billion, a 10% year-over-year increase that surpassed Wall Street consensus estimates of $7.4 billion. This revenue beat was primarily driven by robust performance in its foundational business units, specifically the HIV portfolio, the oncology drug Trodelvy, and the liver disease treatment Livdelzi. HIV sales, the company’s largest segment, grew by 12% to $5.69 billion. Within this portfolio, the HIV prevention drug Descovy saw a remarkable 48% surge to $967 million, while Biktarvy, the company’s flagship HIV treatment, contributed $3.8 billion in sales, reflecting a 7% annual increase.

Despite the strong operational metrics, Gilead posted a significant net loss of $10.5 billion, or $8.45 per share, a sharp reversal from the $1.96 billion profit recorded in the same period last year. The primary culprit behind this swing was a non-GAAP charge of $9.08 per share related to acquired in-process research and development (IPR&D) expenses. These charges stem from recent acquisitions of cell therapy firm Arcellx, autoimmune drug developer Ouro Medicines, and cancer drug developer Tubulis GmbH. When stripping out these one-time acquisition costs, the company reported an adjusted loss of $6.75 per share, which still represented a decline from the previous year’s adjusted earnings of $2.01 per share but beat analyst expectations of a $7.31 loss.

The company’s management team, led by Chairman and CEO Daniel O’Day, emphasized the strength of the underlying base business during earnings communications. O’Day highlighted that the 10% year-over-year growth in product sales, excluding the COVID-19 drug Veklury, demonstrated the resilience of Gilead’s core franchises. Beyond the HIV segment, Trodelvy sales grew 26% to $457 million, and liver disease drug sales rose 10% to $877 million. Additionally, the newly launched HIV prevention injection Yeztugo generated $232 million in quarterly sales, exceeding the $210 million forecast and reinforcing management’s confidence in its potential to reach $1 billion in annual sales.

However, the earnings report was not without headwinds. Sales of Veklury plummeted 81% to $23 million, a consequence of declining COVID-19 hospitalization rates globally. Consequently, Gilead lowered its full-year sales forecast for Veklury to approximately $300 million, down from a previous estimate of $600 million. This decline in a legacy revenue stream adds pressure to the company’s transition toward its newer oncology and HIV pipelines. Furthermore, the balance sheet reflects the aggressive capital deployment required for recent M&A activity; cash and equivalents dropped to $3.2 billion from $10.6 billion at the end of 2025, largely due to $11.3 billion in acquisition-related outflows and debt repayments.

Looking ahead, Gilead raised its full-year 2026 product sales guidance to a range of $30.1 billion to $30.4 billion, slightly lifting the lower bound from the previous estimate of $30.0 billion. The midpoint of $30.25 billion exceeds typical analyst expectations for full-year product sales. The company also improved its adjusted loss per share guidance for the year to a range of -$0.65 to -$0.30, narrowing the previously projected loss of -$1.05 to -$0.65. Despite the improved guidance, the full-year projected loss remains a point of contention for some investors, particularly as the company navigates the integration of its new assets and the phase-out of pandemic-era revenues. The market’s positive reaction, evidenced by the stock’s 3.13% rise and record trading volume, suggests that investors are prioritizing the strength of the HIV and oncology franchises over the accounting impacts of recent acquisitions.